{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:42:03Z","timestamp":1769517723003,"version":"3.49.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1999,8,1]],"date-time":"1999-08-01T00:00:00Z","timestamp":933465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Mol Neurobiol"],"published-print":{"date-parts":[[1999,8]]},"DOI":"10.1023\/a:1006938908284","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T08:03:52Z","timestamp":1040544232000},"page":"491-510","source":"Crossref","is-referenced-by-count":41,"title":["Metabolism, Pharmacogenetics, and Metabolic Drug\u2013Drug Interactions of Antipsychotic Drugs"],"prefix":"10.1007","volume":"19","author":[{"given":"J.","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W.","family":"Gorrod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"220440_CR1","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1001\/jama.1973.03220270026008","volume":"224","author":"S. C. Alvarez-Mena","year":"1973","unstructured":"Alvarez-Mena, S. C., and Frank, M. J. (1973). Phenothiazine-induced T-wave abnormalities. Effects of overnight fasting. JAMA\n224:1730\u20131733.","journal-title":"JAMA"},{"key":"220440_CR2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"J. M. Alvir","year":"1993","unstructured":"Alvir, J. M., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., and Schaaf, J. A. (1993). Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N. Engl. J. Med.\n329:162\u2013167.","journal-title":"N. Engl. J. Med."},{"key":"220440_CR3","first-page":"650","volume":"143","author":"G. W. Arana","year":"1985","unstructured":"Arana, G. W., Goff, D. C., Friedman, H., Ornsteen, M., Greenblatt, D. J., Black, B., and Shader, R. I. (1985). Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am. J. Psychiatry\n143:650\u2013651.","journal-title":"Am. J. Psychiatry"},{"key":"220440_CR4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1253\/jcj.34.391","volume":"34","author":"M. Arita","year":"1970","unstructured":"Arita, M., and Mashiba, H. (1970). Effects of phenothiazine and propranolol on ECG. The effects of propranolol on the electrocardiographic abnormalities induced by phenothiazine derivatives. Jpn. Circ. J.\n34:391\u2013400.","journal-title":"Jpn. Circ. J."},{"key":"220440_CR5","first-page":"587","volume":"21","author":"R. Axelsson","year":"1977","unstructured":"Axelsson, R. (1977). On the serum concentrations and antipsychotic effects of thioridazine, thioridazine side-chain sulfoxide and thioridazine side-chain sulfone. Curr. Ther. Res.\n21:587\u2013605.","journal-title":"Curr. Ther. Res."},{"key":"220440_CR6","first-page":"561","volume":"20","author":"R. Axelsson","year":"1977","unstructured":"Axelsson, R., and M\u00e5rtensson, E. (1977). The concentration pattern of nonconjugated thioridazine metabolites in serum by thioridazine treatment and its relationship to physiological and clinical variables. Curr. Ther. Res.\n20:561\u2013586.","journal-title":"Curr. Ther. Res."},{"key":"220440_CR7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0006-3223(94)90601-7","volume":"36","author":"G. B. Baker","year":"1994","unstructured":"Baker, G. B., Coutts, R. T., and Holt, A. (1994). Metabolism and chirality in psychopharmacology. Biol. Psychiatry\n36:211\u2013213.","journal-title":"Biol. Psychiatry"},{"key":"220440_CR8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1994.tb04385.x","volume":"38","author":"L. Bertilsson","year":"1994","unstructured":"Bertilsson, L., Carrillo, J. A., Dahl, M. L., Llerena, A., Alm, C., Bondesson, U., Lindstrom, L., Rodriguez de la Rubia, I., Ramos, S., and Benitez, J. (1994). Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol.\n38:471\u2013473.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"220440_CR9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2165\/00003088-199732030-00004","volume":"32","author":"R. J. Bertz","year":"1997","unstructured":"Bertz, R. J., and Grannerman, G. R. (1997). Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet.\n32:210\u2013258.","journal-title":"Clin. Pharmacokinet."},{"key":"220440_CR10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3109\/00498259509061859","volume":"25","author":"B. L. Blake","year":"1995","unstructured":"Blake, B. L, Rose. R. L., Mailman, R. B., Levi, P. E., and Hodgson, E, (1995). Metabolism of thioridazine by microsomal monooxygenases: Relative roles of P450 and flavin-containing monooxygenase. Xenobiotica\n25: 377\u2013393.","journal-title":"Xenobiotica"},{"key":"220440_CR11","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0022-3565(25)22440-5","volume":"270","author":"J. Bloomquist","year":"1994","unstructured":"Bloomquist, J., King, E., Wright, A., Mytilineou, C., Kimura, K., Castagnoli, K., and Castagnoli, N., Jr. (1994). 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J. Pharmacol. Exp. Ther.\n270:822\u2013830.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"220440_CR12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00426481","volume":"53","author":"L. Bolvig Hansen","year":"1977","unstructured":"Bolvig Hansen, L., and Larsen, N. E. (1977). Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology\n53:127\u2013130.","journal-title":"Psychopharmacology"},{"key":"220440_CR13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.1979.tb00900.x","volume":"7","author":"L. Bolvig Hansen","year":"1979","unstructured":"Bolvig Hansen, L., Elley, J., Rosted Christensen, T., Larsen, N. E., Naestoft, J., and Hvidberg, E. F. (1979). Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs. Br. J. Clin. Pharmacol.\n7:75\u201380.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"220440_CR14","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF00432736","volume":"74","author":"L. Bolvig Hansen","year":"1981","unstructured":"Bolvig Hansen, L., Larsen, N. E., and Vesterg\u00e5rd, P. (1981). Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology\n74:306\u2013309.","journal-title":"Psychopharmacology"},{"key":"220440_CR15","first-page":"1352","volume":"146","author":"R. H. Bouchard","year":"1989","unstructured":"Bouchard, R. H., Pourcher, E., and Vincent, P. (1989). Fluoxetine and extrapyramidal side effects. Am. J. Psychiatry\n146:1352\u20131353.","journal-title":"Am. J. Psychiatry"},{"key":"220440_CR16","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0090-9556(25)08620-9","volume":"20","author":"M. R. Britto","year":"1992","unstructured":"Britto, M. R., and Wedlund, P. J. (1992). Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes. Drug Metab. Dispos.\n20:446\u2013450.","journal-title":"Drug Metab. Dispos."},{"key":"220440_CR17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00004714-199604000-00010","volume":"16","author":"M. J. Byerley","year":"1996","unstructured":"Byerley, M. J., and DeVane, L. (1996). Pharmacokinetics of clozapine and risperidone: A review of recent literature. J. Clin. Psychopharmcol.\n16:177\u2013187.","journal-title":"J. Clin. Psychopharmcol."},{"key":"220440_CR18","first-page":"1497","volume-title":"Psychopharmacology: The Fourth Generation of Progress","author":"D. E. Casey","year":"1995","unstructured":"Casey, D. E. (1995). Tardive dyskinesia. In Bloom, F. E., and Kupfer, D. J. (eds.) Psychopharmacology: The Fourth Generation of Progress, Raven Press, New York, pp. 1497\u20131502."},{"key":"220440_CR19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1176\/ajp.151.1.123","volume":"151","author":"F. Centorrino","year":"1994","unstructured":"Centorrino, F., Baldessarini, R. J., Kando, J., Frankenburg, F. R., Volpicelli, S. A., Puopolo, P. R., and Flood, J. G. (1994). Serum concentrations of clozapine and its major metabolites: Effects of cotreatment with fluoxetine or valproate. Am. J. Psychiatry\n151:123\u2013125.","journal-title":"Am. J. Psychiatry"},{"key":"220440_CR20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01046700","volume":"34","author":"Y. F. Cheng","year":"1988","unstructured":"Cheng, Y. F., Lundberg, T., Bondesson, U., Lindstrom, L., and Gabrielsson, J. (1988). Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur. J. Clin. Pharmacol.\n34:445\u2013449.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"220440_CR21","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1023\/A:1016434312388","volume":"4","author":"M. G. Choc","year":"1987","unstructured":"Choc, M. G., Lehr, R. G., Hsuan, F., Honigfeld, G., Smith, H. T., Borison, R., and Volavka, J. (1987). Multiple-dose pharmacokinetics of clozapine in patients. Pharma. Res.\n4:402\u2013405.","journal-title":"Pharma. Res."},{"key":"220440_CR22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1023\/A:1015859103824","volume":"7","author":"M. G. Choc","year":"1990","unstructured":"Choc, M. G., Hsuan, F., Honigfeld, G., Robinson, W. T., Ereshefsky, L., Crismon, M. L., Saklad, S. R., Hirschowitz, J., and Wagner, R. (1990). Single-vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharma. Res.\n7:347\u2013351.","journal-title":"Pharma. Res."},{"key":"220440_CR23","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/0165-6147(92)90140-2","volume":"13","author":"S. Cholerton","year":"1992","unstructured":"Cholerton, S., Daly, A. K., and Idle, J. R. (1992). The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci.\n13:434\u2013439.","journal-title":"Trends Pharmacol. Sci."},{"key":"220440_CR24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF00439552","volume":"97","author":"B. M. Cohen","year":"1989","unstructured":"Cohen, B. M., Lipinski, J. F., and Waternaux, C. (1989). A fixed dose study of the plasma concentration and clinical effects of thioridazine and its major metabolites. Psychopharmacology\n97:481\u2013488.","journal-title":"Psychopharmacology"},{"key":"220440_CR25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2165\/00003088-197803010-00002","volume":"3","author":"T. B. Cooper","year":"1978","unstructured":"Cooper, T. B. (1978). Plasma level monitoring of antipsychotic drugs. Clin. Pharmacokinet.\n3:14\u201338.","journal-title":"Clin. Pharmacokinet."},{"key":"220440_CR26","first-page":"30","volume":"19","author":"R. T. Coutts","year":"1994","unstructured":"Coutts, R. T. (1994). Polymorphism in the metabolism of drugs, including antidepressant drugs: Comments on phenotyping. J. Psychiatr. Neurosci.\n19:30\u201344.","journal-title":"J. Psychiatr. Neurosci."},{"key":"220440_CR27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1600-0447.1991.tb01428.x","volume":"84","author":"M. L. Dahl","year":"1991","unstructured":"Dahl, M. L., Ekqvist, B., Widen, J., and Bertilsson, L. (1991). Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr. Scand.\n84:99\u2013102.","journal-title":"Acta Psychiatr. Scand."},{"key":"220440_CR28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2125.1994.tb04242.x","volume":"37","author":"M. L. Dahl","year":"1994","unstructured":"Dahl, M. L., Llerena, A., Bondesson, U., Lindstr\u00f6m, L., and Bertilsson, L. (1994). Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br. J. Clin. Pharmacol.\n37:71\u201374.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"220440_CR29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00007691-198204000-00005","volume":"4","author":"S. G. Dahl","year":"1982","unstructured":"Dahl, S. G. (1982). Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther. Drug Monit.\n4:33\u201340.","journal-title":"Ther. Drug Monit."},{"key":"220440_CR30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.1989.109","volume":"46","author":"M. L. Dahl-Puustinen","year":"1989","unstructured":"Dahl-Puustinen, M. L., Liden, A., Alm, C., and Bertilsson, L. (1989). Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in man. Clin. Pharmacol. Ther.\n46:78\u201381.","journal-title":"Clin. Pharmacol. Ther."},{"key":"220440_CR31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00004714-199410000-00009","volume":"14","author":"D. G. Daniel","year":"1994","unstructured":"Daniel, D. G., Randolph, C., Jaskiw, G., Handel, S., Williams, T., Abi-Dargham, A., Shoaf, S., Egan, M., Elkashef, A., Liboff, S., and Linnoila, M. (1994). Coadministration of fluvoxamine increases serum concentrations of haloperidol. J. Clin. Psychopharmacol.\n14:340\u2013343.","journal-title":"J. Clin. Psychopharmacol."},{"key":"220440_CR32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0009-2797(84)90084-X","volume":"52","author":"N. J. de Mol","year":"1984","unstructured":"de Mol, N. J., and Busker, R. W. (1984). Irreversible binding of the chlorpromazine radical cation and of photoactivated chlorpromazine to biological macromolecules. Chem.-Biol. Interact.\n52:79\u201392.","journal-title":"Chem.-Biol. Interact."},{"key":"220440_CR33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0009-2797(86)90050-5","volume":"57","author":"N. J. de Mol","year":"1986","unstructured":"de Mol, N. J., Becht, A. B. C., Koenen, J., and Lodder, G. (1986). Irreversible binding with biological macromolecules and effects in bacterial mutagenicity tests of the radical cation of promethazine and photoactivated promethazine. Comparison with chlorpromazine. Chem.-Biol. Interact.\n57:73\u201383.","journal-title":"Chem.-Biol. Interact."},{"key":"220440_CR34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00561023","volume":"36","author":"F. Derenne","year":"1989","unstructured":"Derenne, F., Joanne, C., Vandel, S., Bertschy, G., Volmat, R., and Bechtel, P. (1989). Debrisoquine oxidative phenotyping and psychiatric drug treatment. Eur. J. Clin. Pharmacol.\n36:53\u201358.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"220440_CR35","first-page":"755","volume":"67","author":"R. Dom","year":"1967","unstructured":"Dom, R. (1967). Local glial reaction in the CNS of albino-rats in response to the administration of a neuroleptic drug (Butyrophenone). Acta Neurol. Belg.\n67:755\u2013762.","journal-title":"Acta Neurol. Belg."},{"key":"220440_CR36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/(SICI)1099-1077(199701\/02)12:1<5::AID-HUP831>3.0.CO;2-4","volume":"12","author":"S. C. Edge","year":"1997","unstructured":"Edge, S. C., Markowitz, J. S., and DeVane, C. L. (1997). Clozapine drug-drug interactions: A review of the literature. Hum. Psychopharmacol.\n12:5\u201320.","journal-title":"Hum. Psychopharmacol."},{"key":"220440_CR37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1365-2125.1997.t01-1-00605.x","volume":"44","author":"B. Eiermann","year":"1997","unstructured":"Eiermann, B., Engel, G., Johansson, I., Zanger, U. M., and Bertilsson, L. (1997). The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br. J. Clin. Pharmacol.\n44:439\u2013446.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"220440_CR38","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/clpt.1994.172","volume":"56","author":"D. W. Eyles","year":"1994","unstructured":"Eyles, D. W., McLennan. H. R., Jones, A., McGrath, J. J., Stedman, T. J., and Pond, S. M. (1994). Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin. Pharmacol. Ther.\n56:512\u2013520.","journal-title":"Clin. Pharmacol. Ther."},{"key":"220440_CR39","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1139\/y96-145","volume":"74","author":"J. Fang","year":"1997","unstructured":"Fang, J. (1997). Amphetamine-like behavioural effects induced by perinigral injection of the pyridinium metabolite of haloperidol in rat. Can. J. Physiol. Pharmacol.\n74:1359\u20131361.","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"220440_CR40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0378-4274(91)90062-B","volume":"59","author":"J. Fang","year":"1991","unstructured":"Fang, J., and Gorrod, J. W. (1991). Dehydration is the first step in the biotransformation of haloperidol to its pyridinium metabolite. Toxicol. Lett.\n59:117\u2013123.","journal-title":"Toxicol. Lett."},{"key":"220440_CR41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0378-4347(93)80318-X","volume":"614","author":"J. Fang","year":"1993","unstructured":"Fang, J., and Gorrod, J. W. (1993). An HPLC system for the analysis of haloperidol and seven of its metabolites in microsomal preparations. J. Chromatogr.\n614:267\u2013273.","journal-title":"J. Chromatogr."},{"key":"220440_CR42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF02246078","volume":"121","author":"J. Fang","year":"1995","unstructured":"Fang, J., and Yu, P. H., (1995). Effects of haloperidol and its metabolites on dopamine and noradrenaline uptake in rat brain preparations. Psychopharmacology\n121:379\u2013384.","journal-title":"Psychopharmacology"},{"key":"220440_CR43","first-page":"121","volume":"22","author":"J. Fang","year":"1993","unstructured":"Fang, J., Gorrod, J. W., Kajbaf, M., Lamb, J. H., and Nalyor, S. (1993). Investigation of the neuroleptic drug haloperidol and its metabolites using tandem mass spectro. Int. J. Mass Spectrometry Ion Process.\n22:121\u2013131.","journal-title":"Int. J. Mass Spectrometry Ion Process."},{"key":"220440_CR44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/BF02246077","volume":"121","author":"J. Fang","year":"1995","unstructured":"Fang, J., Zuo, D. M., and Yu, P. H. (1995a). A comparison of a quaternary pyridinium metabolite of haloperidol (HP+) with the neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology\n121:373\u2013378.","journal-title":"Psychopharmacology"},{"key":"220440_CR45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF02245841","volume":"118","author":"J. Fang","year":"1995","unstructured":"Fang, J., Yu, P. H., Gorrod, J. W., and Boulton, A. A. (1995b). Inhibition of monoamine oxidase by haloperidol and its metabolites: Pharmacological implications for the chemotherapy of schizophrenia. Psychopharmacology\n118:206\u2013212.","journal-title":"Psychopharmacology"},{"key":"220440_CR46","first-page":"125","volume":"12","author":"J. Fang","year":"1996","unstructured":"Fang, J., Lai, C. T., and Yu, P. H. (1996a). Neurotoxic effects of 4-(4-chlorophenyl-1-[4-(4-fluorophenyl)-4-oxobutyl]-pyridinium (HP+), a major metabolite of haloperidol, on dopaminergic systems in vitro and in vivo. Biogen. Amines\n12:125\u2013134.","journal-title":"Biogen. Amines"},{"key":"220440_CR47","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/PL00005298","volume":"358","author":"J. Fang","year":"1998","unstructured":"Fang, J., Coutts, R. T., McKenna, K. F., and Baker, G. B. (1998). Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn-Schmiedeberg's Arch. Pharmacol.\n358:592\u2013599.","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"220440_CR48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0378-4347(96)00075-8","volume":"682","author":"J. Fang","year":"1996","unstructured":"Fang, J., Baker, G. B., and Coutts, R. T. (1996c). Determination of 4-chlorophenyl-4-hydroxypiperidine, a metabolite of haloperidol, by gas chromatography with electron-capture detection. J. Chromatogr. Biomed. Appl.\n682:283\u2013288.","journal-title":"J. Chromatogr. Biomed. Appl."},{"key":"220440_CR49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1026317929335","volume":"17","author":"J. Fang","year":"1997","unstructured":"Fang, J., Baker, G. B., Silverstone, P. H., and Coutts, R. T. (1997). Involvement of CYP3A4 and CYP2D6 in a number of major metabolic pathways of haloperidol. Cell Mol. Neurobiol.\n17:227\u2013233.","journal-title":"Cell Mol. Neurobiol."},{"key":"220440_CR50","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0022-3565(25)11451-1","volume":"260","author":"V. Fischer","year":"1992","unstructured":"Fischer, V., Vogels, B., Maurer, G., and Tynes, R. E. (1992). The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J. Pharmacol. Exp. Ther.\n260:1355\u201360.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"220440_CR51","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/0006-2952(88)90063-9","volume":"37","author":"R. Fonne-Pfister","year":"1988","unstructured":"Fonne-Pfister, R., and Meyer, U. A. (1988). Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, and target of the debrisoquine\/sparteine type polymorphism. Biochem. Pharmacol.\n37:3829\u20133835.","journal-title":"Biochem. Pharmacol."},{"key":"220440_CR52","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1520\/JFS10149J","volume":"17","author":"I. S. Forrest","year":"1972","unstructured":"Forrest, I. S., and Green, D. E. (1972). Phenothiazines: metabolism and analytical detection. J. Forens. Sci.\n17:592\u2013617.","journal-title":"J. Forens. Sci."},{"key":"220440_CR53","first-page":"53","volume":"2","author":"F. M. Forrest","year":"1970","unstructured":"Forrest, F. M., Forrest, I. S., and Serra, M. T. (1970). Modification of chlorpromazine metabolism by some other drugs frequently administered to psychiatric patients. Biol. Psychiatry\n2:53\u201358.","journal-title":"Biol. Psychiatry"},{"key":"220440_CR54","first-page":"567","volume":"24","author":"A. Forsman","year":"1978","unstructured":"Forsman, A., and Larsson, M. (1978). Metabolism of haloperidol. Curr. Ther. Res.\n24:567\u2013568.","journal-title":"Curr. Ther. Res."},{"key":"220440_CR55","first-page":"943","volume":"48","author":"A. Gaedigk","year":"1991","unstructured":"Gaedigk, A., Blum, M., Gaedigk, R., Eichelbaum, M., and Meyer, U. A. (1991). Deletion of the entire cytrochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine\/sparteine polymorphism. Am. J. Hum. Genet.\n48:943\u2013950.","journal-title":"Am. J. Hum. Genet."},{"key":"220440_CR56","first-page":"120","volume-title":"Epileptic Seizures-Behavior-Pain","author":"A. R. Gagneux","year":"1976","unstructured":"Gagneux, A. R. (1976). The chemistry of cabamazepine. In Birkmayer, B. (ed.), Epileptic Seizures-Behavior-Pain, Hans Huber, Berne, pp. 120\u2013126."},{"key":"220440_CR57","first-page":"667","volume":"26","author":"R. Gauch","year":"1971","unstructured":"Gauch, R., and Michaelis, W. (1971). The metabolism of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine (clozapine) in mice, dogs and human subjects. Farmaco Ed. Pratica\n26:667\u2013681.","journal-title":"Farmaco Ed. Pratica"},{"key":"220440_CR58","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2141.1994.tb04786.x","volume":"86","author":"S. L. Gerson","year":"1994","unstructured":"Gerson, S. L., Arce, C., and Meltzer, H. Y. (1994). N-Desmethylclozapine: A clozapine metabolite that suppresses haemopoiesis. Br. J. Haematol.\n86:555\u2013561.","journal-title":"Br. J. Haematol."},{"key":"220440_CR59","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/archpsyc.1984.01790170097011","volume":"41","author":"W. M. Glazer","year":"1984","unstructured":"Glazer, W. M., Moore, D. C., Schooler, N. R., Brenner, L. M., and Morgenstern, H. (1984). Tardive dyskinesia: A discontinuation study. Arch. Gen. Psychiatry\n41:623\u2013627.","journal-title":"Arch. Gen. Psychiatry"},{"key":"220440_CR60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/(SICI)1099-1077(199603)11:2<97::AID-HUP759>3.0.CO;2-7","volume":"11","author":"P. Glue","year":"1996","unstructured":"Glue, P., and Banfield, C. (1996). Psychiatry, psychopharmacology and P-450s. Hum. Psychopharmacol.\n11:97\u2013114.","journal-title":"Hum. Psychopharmacol."},{"key":"220440_CR61","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1176\/ajp.147.4.492","volume":"147","author":"D. C. Goff","year":"1990","unstructured":"Goff, D. C., Brotman, A. W., Waites, M., and McCormick, S. (1990). Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am. J. Psychiatry\n147:492\u2013494.","journal-title":"Am. J. Psychiatry"},{"key":"220440_CR62","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1176\/ajp.148.6.790","volume":"148","author":"D. C. Goff","year":"1991","unstructured":"Goff, D. C., Midha, K. K., Brotman, A. W., Waites, M., and Baldessarini, R. J. (1991). Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am. J. Psychiatry\n148:790\u2013794.","journal-title":"Am. J. Psychiatry"},{"key":"220440_CR63","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3109\/00498259309059390","volume":"23","author":"J. W. Gorrod","year":"1993","unstructured":"Gorrod, J. W., and Fang, J. (1993). On the metabolism of haloperidol. Xenobiotica\n23:495\u2013508.","journal-title":"Xenobiotica"},{"key":"220440_CR64","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/bmj.1.5798.463","volume":"1","author":"L. F. Gram","year":"1972","unstructured":"Gram, L. F., and Fredricson Over\u00f8, K. (1972). Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br. Med. J.\n1:463\u2013465.","journal-title":"Br. Med. J."},{"key":"220440_CR65","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1365-2125.1989.tb05362.x","volume":"27","author":"L. F. Gram","year":"1989","unstructured":"Gram, L. F., Debruyne, D., Caillard, V., Boulenger, J. P., Lacotte, J., Moulin, M., and Zarifian, E. (1989). Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br. J. Clin. Pharmacol.\n27:272\u2013275.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"220440_CR66","first-page":"673","volume":"39","author":"D. J. Greenblatt","year":"1978","unstructured":"Greenblatt, D. J., Gross, P. L., Harris, J., Shader R. I. and Ciraulo, D. A. (1978). Fatal hyperthermia following haloperidol therapy of sedative-hypnotic withdrawal. J. Clin. Psychiatry\n39:673\u2013675.","journal-title":"J. Clin. Psychiatry"},{"key":"220440_CR67","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0041-008X(86)90398-4","volume":"86","author":"P. W. Hale","year":"1986","unstructured":"Hale, P. W., and Poklis, A. (1986). Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart. Toxicol. Appl. Pharmacol.\n86:44\u201355.","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"220440_CR68","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0306-4522(90)90154-V","volume":"34","author":"T. Hansson","year":"1990","unstructured":"Hansson, T., Tindberg, N., Ingelman-Sundberg, M., and K\u00f6hler, C. (1990). Regional distribution of ethanol-inducible cytochrome P450 IIE1 in the rat central nervous system. Neuroscience\n34:451\u2013463.","journal-title":"Neuroscience"},{"issue":"Suppl.","key":"220440_CR69","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/BF00442557","volume":"99","author":"C. Haring","year":"1989","unstructured":"Haring, C., Meise, U., Humpel, C., Saria, A., Fleischhacker, W. W., and Hinterhuber, H. (1989). Dose-related plasma levels of clozapine: Influence of smoking behaviour, sex and age. Psychopharmacology\n99(Suppl.):38\u201340.","journal-title":"Psychopharmacology"},{"key":"220440_CR70","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00004714-199312000-00003","volume":"13","author":"M. Hasegawa","year":"1993","unstructured":"Hasegawa, M., Gutierrez-Esteinou, R., Way, L., and Meltzer, H. (1993). Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking. J. Clin. Psychopharmacol.\n13:383\u2013390.","journal-title":"J. Clin. Psychopharmacol."},{"key":"220440_CR71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199503000-00003","volume":"10","author":"H. He","year":"1995","unstructured":"He, H., and Richardson, J. S. (1995). A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int. Clin. Psychopharmacol.\n10:19\u201330.","journal-title":"Int. Clin. Psychopharmacol."},{"key":"220440_CR72","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0026-895X(25)09238-7","volume":"50","author":"E. Hedlund","year":"1996","unstructured":"Hedlund, E., Wyss, A., Kainu, T., Backlund, M., K\u00f6hler C., Pelto-Huikko, M., Gustafsson, J.-\u00c5., and Warner, M. (1996). Cytochrome P4502D4 in the brain: Specific neuronal regulation by clozapine and toluene. Mol. Pharmacol.\n50:342\u2013350.","journal-title":"Mol. Pharmacol."},{"issue":"Suppl.","key":"220440_CR73","first-page":"13","volume":"55","author":"J. Heykants","year":"1994","unstructured":"Heykants, J., Huang, M. L., Mannens, G., Meuldermans, W., Snoeck, E., Van Beijsterveldt, L., Van Peer, A., and Woestenborghs, R. (1994). The pharmacokinetics of risperidone in humans: A summary. J. Clin. Psychiatry.\n55(Suppl.):13\u201317.","journal-title":"J. Clin. Psychiatry."},{"key":"220440_CR74","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-199408000-00011","volume":"14","author":"C. Hiemke","year":"1994","unstructured":"Hiemke, C., Weigmann, H., Hartter, S., Dahmen, N., Wetzel, H., and Muller, H. (1994). Elevated levels of clozapine in serum after addition of fluvoxamine. J. Clin. Psychopharmacol.\n14:279\u201381.","journal-title":"J. Clin. Psychopharmacol."},{"key":"220440_CR75","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF00613934","volume":"24","author":"C. A. Howes","year":"1983","unstructured":"Howes, C. A., Pullar, T., Sourindhrin, I., Mistra, P. C., Capel, H., Lawson, D. H., and Tilstone, W. J. (1983). Reduced steady-state plasma concentrations of chlorpromazine and indomethacin in patients receiving cimetidine. Eur. J. Clin. Pharmacol.\n24:99\u2013102.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"220440_CR76","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1192\/S0007125000292556","volume":"163","author":"J. W. Hubbard","year":"1993","unstructured":"Hubbard, J. W., Midha, K. K., Hawes, E. M., McKay, G., Marder, S. R., Aravagiri, M., and Korchinski, E. D. (1993). Metabolism of phenothiazine and butyrophenone antipsychotic drugs: A review of some recent research findings and clinical implications. Br. J. Psychiatry\n163:19\u201324.","journal-title":"Br. J. Psychiatry"},{"key":"220440_CR77","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0090-9556(25)08764-1","volume":"17","author":"T. Inaba","year":"1989","unstructured":"Inaba, T., and Kovacs, J. (1989). Haloperidol reductase in human and guinea pig livers. Drug Metab. Dispos.\n17:330\u2013333.","journal-title":"Drug Metab. Dispos."},{"key":"220440_CR78","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0090-9556(25)08231-5","volume":"13","author":"T. Inaba","year":"1985","unstructured":"Inaba, T., Jurima, M., Mahon, W. A., and Kalow, W. (1985). In vitro inhibition of human liver cytochrome P450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab. Dispos.\n13:443\u2013448.","journal-title":"Drug Metab. Dispos."},{"key":"220440_CR79","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00004714-198504000-00010","volume":"5","author":"M. W. Jann","year":"1985","unstructured":"Jann, M. W., Ereshefsky, L., Saklad, S. R., Seidel, D. R., Davis, C. M., Burch, N. R., and Bowden, C. L. (1985). Effects of carbamazepine on plasma haloperidol levels. J. Clin. Psychopharmacol.\n5:106\u2013109.","journal-title":"J. Clin. Psychopharmacol."},{"key":"220440_CR80","first-page":"468","volume":"90","author":"M. W. Jann","year":"1986","unstructured":"Jann, M. W., Saklad, S. R., Ereshefsky, L. O., Richards, A. L., Harrington, C. A., and Davis, C. M. (1986). Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology\n90:468\u2013470.","journal-title":"Psychopharmacology"},{"key":"220440_CR81","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-1781(89)90043-7","volume":"28","author":"M. W. Jann","year":"1989","unstructured":"Jann, M. W., Fidone, G. S., Hernandez, J. M., Amrung, S., and Davis, C. M. (1989). Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation. Psychiatry Res.\n28:153\u2013159.","journal-title":"Psychiatry Res."},{"key":"220440_CR82","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","volume":"16","author":"M. Jerling","year":"1994","unstructured":"Jerling, M., Lindstrom, L., Bondesson, U., and Bertilsson, L. (1994). Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther. Drug Monit.\n16:368\u2013374.","journal-title":"Ther. Drug Monit."},{"key":"220440_CR83","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2125.1990.tb03827.x","volume":"30","author":"J. Kallio","year":"1990","unstructured":"Kallio, J., Huupponen, R., Seppala, M., Sako, E. and Iisalo, E. (1990). The effect of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine. Br. J. Clin. Pharmacol.\n30:638\u2013643.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"220440_CR84","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"Kane, J., Honigfeld, G., Singer, J., Meltzer, H. Y., Clozaril\u00ae Collaborative Study Group","year":"1988","unstructured":"Kane, J., Honigfeld, G., Singer, J., Meltzer, H. Y., Clozaril\u00ae Collaborative Study Group (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry\n45:789\u2013796.","journal-title":"Arch. Gen. Psychiatry"},{"key":"220440_CR85","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0003-9861(91)90301-X","volume":"284","author":"P. P. Kelder","year":"1991","unstructured":"Kelder, P. P., Fischer, M. J. E., de Mol, N. J., and Janssen, L. H. M. (1991). Oxidation of chlorproazine by methemoglobin in the presence of hydrogen peroxide. Formation of chlorpromazine radical cation and its covalent binding to methemoglobin. Arch. Biochem. Biophys.\n284:313\u2013319.","journal-title":"Arch. Biochem. Biophys."},{"key":"220440_CR86","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/jnr.490390509","volume":"39","author":"G. Kempermann","year":"1994","unstructured":"Kempermann, G., Knoth, R., Gebiicke-Haerter, P. J., Stolz, B. J., and Volk, B. (1994). Cytochrome P450 in rat astrocytes in vivo and in vitro: Intracellular localization and induction by phenytoin. J. Neurosci. Res.\n39:576\u2013588.","journal-title":"J. Neurosci. Res."},{"key":"220440_CR87","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0006-3223(85)90087-3","volume":"20","author":"R. Kidron","year":"1985","unstructured":"Kidron, R., Averbuch, I., Klein, E., and Belmaker, R. H. (1985). Carbamazepine induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol. Psychiatry\n20:219\u2013222.","journal-title":"Biol. Psychiatry"},{"key":"220440_CR88","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archpsyc.1984.01790130061009","volume":"41","author":"E. Klein","year":"1984","unstructured":"Klein, E., Bental, E., Lerer, B., and Belmaker, R. H. (1984). Combination of carbamazepine and haloperidol versus placebo and haloperidol in excited psychoses: A controlled study. Arch. Gen. Psychiatry\n41:165\u2013170.","journal-title":"Arch. Gen. Psychiatry"},{"key":"220440_CR89","first-page":"51","volume":"27","author":"J. Koizumi","year":"1973","unstructured":"Koizumi, J., and Shiraishi, H. (1973). Synaptic changes in the rabbit pallidum following long-term haloperidol adminstration. Folia Psychiatr. Neurol. Jpn.\n27:51\u201357.","journal-title":"Folia Psychiatr. Neurol. Jpn."},{"key":"220440_CR90","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/0006-2952(85)90017-6","volume":"34","author":"E. R. Korpi","year":"1985","unstructured":"Korpi, E. R., Costakos, D. T., and Wyatt, R. J. (1985). Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes. Biochem. Pharmacol.\n34:2923\u20132927.","journal-title":"Biochem. Pharmacol."},{"key":"220440_CR91","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/BF00562943","volume":"11","author":"P. Kragh-S\u00f8rensen","year":"1977","unstructured":"Kragh-S\u00f8rensen, P., Borg\u00e5, O, Garle, M., Bolvig Hansen, L., Hansen, C. E., Hvidberg, E. F., Larsen, N. E., and Sjoqvist, F. (1977). Effect of simultaneous treatment with low doses of perphenazine on plasma and urine concentrations of nortriptyline and 10-hydroxynortriptyline. Eur. J. Clin. Pharmacol.\n11:479\u2013483.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"220440_CR92","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/BF00442575","volume":"99","author":"P. Krupp","year":"1989","unstructured":"Krupp, P., and Barnes, P. (1989). Leponex-associated granulocytopenia: A review of the situation. Psychopharmacology\n99 (Suppl.):118\u201321.","journal-title":"Psychopharmacology"},{"key":"220440_CR93","first-page":"943","volume":"20","author":"P. J. Lewi","year":"1970","unstructured":"Lewi, P. J., Heykants, J. J. P., Allewijn, F. T. N., Dony, J. G. H., and Janssen, P. A. J. (1970). Distribution and metabolism of neuroleptic drugs, part 1: Pharmacokinetics of haloperidol. Arzneimittelforschung\n20:943\u2013948.","journal-title":"Arzneimittelforschung"},{"key":"220440_CR94","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0022-3565(25)23635-7","volume":"248","author":"J. J. Liccione","year":"1989","unstructured":"Liccione, J. J., and Maines, M. D. (1989). Manganese-mediated increase in rat brain mitochondrial cytochrome P-450 and drug metabolism activity\u2014Susceptibility of the striatum. J. Pharmacol. Exp. Ther.\n248:222\u2013228.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"220440_CR95","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3109\/00498259309059422","volume":"23","author":"G. Lin","year":"1993","unstructured":"Lin, G., Hawes E. M., McKay, G., Korchinski, E. D., and Midha, K. K., (1993). Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat. Xenobiotica\n23:1059\u20131074.","journal-title":"Xenobiotica"},{"key":"220440_CR96","first-page":"1379","volume":"25","author":"K. Linnet","year":"1997","unstructured":"Linnet, K., and Oleson, O. V. (1997). Metabolism of clozapine by cDNA expressed human cytochrome P450 enzymes. Drug Metab. Dispos.\n25:1379\u20131382.","journal-title":"Drug Metab. Dispos."},{"key":"220440_CR97","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1176\/ajp.137.7.819","volume":"137","author":"M. Linnoila","year":"1980","unstructured":"Linnoila, M., Viukari, M., Vaisanen, K., and Auvinen, J. (1980). Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am. J. Psychiatry\n137:819\u2013821.","journal-title":"Am. J. Psychiatry"},{"key":"220440_CR98","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00007691-199204000-00003","volume":"14","author":"A. Llerena","year":"1992","unstructured":"Llerena, A., Alm, C., Dahl, M. L, Ekqvist, B., and Bertilsson, L. (1992). Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug Monit.\n14:92\u201397.","journal-title":"Ther. Drug Monit."},{"key":"220440_CR99","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/clpt.1993.197","volume":"54","author":"A. Llerena","year":"1993","unstructured":"Llerena, A., Herra\u00edz, A. G., Cobaleda, J., Johansson, I., and Dahl, M. L. (1993). Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin. Pharmacol. Ther.\n54:606\u2013611.","journal-title":"Clin. Pharmacol. Ther."},{"key":"220440_CR100","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","volume":"21","author":"G. Mannens","year":"1993","unstructured":"Mannens, G., Huang, M. L., Meuldermans, W., Hendrickx, J., Woestenborghs, R., and Heykants, J. (1993). Absorption, metabolism, and excretion of risperidone in humans. Drug Metab. Dispo.\n21:1134\u20131141.","journal-title":"Drug Metab. Dispo."},{"key":"220440_CR101","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF02245439","volume":"114","author":"A. A. Megens","year":"1994","unstructured":"Megens, A. A., Awouters, F. H., Schotte, A., Meert, T. F., Dugovic, C., Niemegeers, C. J., and Leysen, J. E. (1994) Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology\n114:9\u201323.","journal-title":"Psychopharmacology"},{"key":"220440_CR102","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1176\/ajp.150.11.1630","volume":"150","author":"H. Y. Meltzer","year":"1993","unstructured":"Meltzer, H. Y., Cola, P., Way, L., Thompson, P. A., Bastani, B., Davies, M. A., and Snitz, B. (1993). Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am. J. Psychiatry\n150:1630\u20131638.","journal-title":"Am. J. Psychiatry"},{"key":"220440_CR103","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/0006-8993(89)90867-6","volume":"489","author":"C. K. Meshul","year":"1989","unstructured":"Meshul, C. K., and Casey, D. E. (1989). Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res.\n489:338\u2013346.","journal-title":"Brain Res."},{"key":"220440_CR104","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/BF02247334","volume":"125","author":"C. K. Meshul","year":"1996","unstructured":"Meshul, C. K., Andreassen, O. A., Allen, C., and Jorgensen, H. A. (1996). Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Psychopharmacology\n125:238\u2013247.","journal-title":"Psychopharmacology"},{"key":"220440_CR105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0090-9556(25)08286-8","volume":"22","author":"W. Meuldermans","year":"1994","unstructured":"Meuldermans, W., Hendricks, J., Mannens, G., Lavrijsen, K., Janssen, C., Bracke, J., Le Jeune, L., Lauwers, W., and Heykants, J. (1994). The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab. Dispo.\n22:129\u2013138.","journal-title":"Drug Metab. Dispo."},{"key":"220440_CR106","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/BF00316110","volume":"39","author":"G. W. Meyer","year":"1990","unstructured":"Meyer, G. W., Woggon, B., Baumann, P., and Meyer, U. A. (1990). Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur. J. Clin. Pharmacol.\n39:613\u2013614.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"220440_CR107","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00004714-198904000-00005","volume":"9","author":"K. K. Midha","year":"1989","unstructured":"Midha, K. K., Chakraborty, B. S., Ganes, D. A., Hawes, E. M., Hubbard, J. W., Keegan, D. L., Korchinski, E. D., and McKay, G. (1989). Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. J. Clin. Psychopharmacol.\n9:98\u2013104.","journal-title":"J. Clin. Psychopharmacol."},{"key":"220440_CR108","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/00004714-198710000-00026","volume":"7","author":"K. K. Midha","year":"1987","unstructured":"Midha, K. K., Hawes, E. M., Hubbard, J. W., Korchinski, E. D., and McKay, G. (1987). Interconversion between haloperidol and reduced haloperidol in humans. J. Clin. Psychopharmacol.\n7:362\u2013364.","journal-title":"J. Clin. Psychopharmacol."},{"key":"220440_CR109","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0006-3223(90)90488-N","volume":"28","author":"D. D. Miller","year":"1990","unstructured":"Miller, D. D., Kelly, M. W., Perry, P. J., and Coryell, W. H., (1990). The influence of cigarette smoking on haloperidol pharmacokinetics. Biol. Psychiatry\n28:529\u2013531.","journal-title":"Biol. Psychiatry"},{"key":"220440_CR110","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/chromsci\/12.12.779","volume":"12","author":"R. G. Muusze","year":"1974","unstructured":"Muusze, R. G., and Huber, J. F. K. (1974). Determination of the psychotropic drug thioridazine and its metabolites in blood by means of high pressure liquid chromatography in combination with fluorometric reaction detection. J. Chromatog. Sci.\n12:779\u2013787.","journal-title":"J. Chromatog. Sci."},{"key":"220440_CR111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dna.1993.12.1","volume":"12","author":"D. R. Nelson","year":"1993","unstructured":"Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. L., Estabrook, R. W., Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O., Okuda, K., and Nebert, D. W. (1993). The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol.\n12:1\u201351.","journal-title":"DNA Cell Biol."},{"key":"220440_CR112","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1176\/ajp.137.10.1232","volume":"137","author":"J. C. Nelson","year":"1980","unstructured":"Nelson, J. C., and Jatlow, P. I. (1980). Neuroleptic effect on desipramine steady-state plasma concentrations. Am. J. Psychiatry\n137:1232\u20131234.","journal-title":"Am. J. Psychiatry"},{"key":"220440_CR113","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00498552","volume":"299","author":"R. \u00d6hman","year":"1977","unstructured":"\u00d6hman, R., Larsson, M., Nilsson, I. M., Engel, J., and Carlsson, A. (1977). Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain. Naunyn-Schmiedeberg Arch. Pharmacol.\n299:105\u2013114.","journal-title":"Naunyn-Schmiedeberg Arch. Pharmacol."},{"key":"220440_CR114","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0163-7258(90)90030-6","volume":"45","author":"A. B. Okey","year":"1990","unstructured":"Okey, A. B. (1990). Enzyme induction in the cytochrome P-450 system. Pharmacol. Ther.\n45:241\u2013298.","journal-title":"Pharmacol. Ther."},{"key":"220440_CR115","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0014-2999(78)90097-3","volume":"49","author":"M. Olianas","year":"1978","unstructured":"Olianas, M., De Montis, G. M., Concu, A., Tagliamonte, A., and Di Chiara, G. (1978). Intranigral kainic acid: Evidence for nigral non-dopaminergic neurons controlling posture and behavior in manner opposite to the dopaminergic ones. Eur. J. Pharmacol.\n49:223\u2013232.","journal-title":"Eur. J. Pharmacol."},{"key":"220440_CR116","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0009-9236(97)90037-0","volume":"62","author":"V. Ozdemir","year":"1997","unstructured":"Ozdemir, V., Naranjo, C. A., Herrmann, N., Reed, K., Sellers, E. M., and Kalow, W. (1997). Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo. Clin. Pharmacol. Ther.\n62:334\u2013347.","journal-title":"Clin. Pharmacol. Ther."},{"key":"220440_CR117","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1365-2125.1997.t01-1-00629.x","volume":"44","author":"L. P. Pan","year":"1997","unstructured":"Pan, L. P., Wijnant, P., DeVriendt, C., Rosseel, M. T., and Belpaire, F. M. (1997). Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br. J. Clin. Pharmacol.\n44:557\u2013564.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"220440_CR118","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/clpt.1982.72","volume":"31","author":"E. J. Pantuck","year":"1982","unstructured":"Pantuck, E. J., Pantuck, C. B., Anderson, K. E., Conney, A. H., and Kappas, A. (1982). Cigarette smoking and chlorpromazine disposition and actions. Clin. Pharmacol. Ther.\n31:533\u2013538.","journal-title":"Clin. Pharmacol. Ther."},{"key":"220440_CR119","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3109\/00498258609038987","volume":"16","author":"A. S. Papadopoulos","year":"1986","unstructured":"Papadopoulos, A. S., and Crammer, J. L., (1986). Suphoxide metabolites of thioridazine in man. Xenobiotica\n16:1097\u20131107.","journal-title":"Xenobiotica"},{"key":"220440_CR120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/00498258509045365","volume":"15","author":"A. S. Papadopoulos","year":"1985","unstructured":"Papadopoulos, A. S., Crammer, J. L., and Cowan, D. A. (1985). Phenolic metabolites of thioridazine in man. Xenobiotica\n15:309\u2013316.","journal-title":"Xenobiotica"},{"key":"220440_CR121","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1192\/bjp.139.2.112","volume":"139","author":"M. Peet","year":"1981","unstructured":"Peet, M., Middlemiss, D. N., and Yates, R. A. (1981). Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine. Br. J. Psychiatry\n139:112\u2013117.","journal-title":"Br. J. Psychiatry"},{"key":"220440_CR122","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/0006-2952(90)90247-I","volume":"40","author":"R. Perrin","year":"1990","unstructured":"Perrin, R., Minn, A., Ghersi-Egea, J. F., Grassiot, M, C., and Seist, G., (1990). Distribution of cytochrome P450 activities towards alkoxyresorufin derivatives in rat brain regions, subcellular fractions and isolated cerebral microvessels. Biochem. Pharmacol.\n40:2145\u20132151.","journal-title":"Biochem. Pharmacol."},{"key":"220440_CR123","first-page":"120","volume":"88","author":"L. H. Piette","year":"1964","unstructured":"Piette, L. H., Bulow, G., and Yamazaki, J. (1964). Electron-paramagnetic-resonance studies of the chlorpromazine free radical formed during enzymatic oxidation by peroxidase-hydrogen peroxide. Biochim. Biophys. Acta\n88:120\u2013129.","journal-title":"Biochim. Biophys. Acta"},{"key":"220440_CR124","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0022-3565(25)24566-9","volume":"272","author":"M. Pirmohamed","year":"1995","unstructured":"Pirmohamed, M., Williams, D., Madden, S., Templeton, E., and Park, B. K. (1995). Metabolism and bioactivation of clozapine by human liver in vitro. J. Pharmacol. Exp. Ther.\n272:984\u2013990.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"220440_CR125","first-page":"169","volume":"150","author":"V. Raitasuo","year":"1993","unstructured":"Raitasuo, V., Lehtovaara, R., and Huttunen, M. O. (1993). Carbamazepine and plasma levels of clozapine. Am. J. Psychiatry\n150:169.","journal-title":"Am. J. Psychiatry"},{"key":"220440_CR126","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-3565(25)12326-4","volume":"276","author":"B. J. Ring","year":"1996","unstructured":"Ring, B. J., Catlow, J., Lindsay, T. J., Gillespie, T., Roskos, L. K., Cerimele, B. J., Swanson, S. P., Hamman, M. A., and Wrighton, S. A., (1996). Identification of the human cytochrome P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pharmacol. Exp. Ther.\n276:658\u2013666.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"220440_CR127","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0022-3565(25)38487-9","volume":"268","author":"H. Rollema","year":"1994","unstructured":"Rollema, H., Skolnik, M., d'Engelbronner, J., Igarashi, K., Usuki, E., and Castagnoli, N., Jr. (1994). MPP+-like neurotoxicity of a pyridinium metabolite derived from haloperidol: In vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther.\n268:380\u2013387.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"220440_CR128","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0026-895X(25)13303-8","volume":"44","author":"B. Schilter","year":"1993","unstructured":"Schilter, B., and Omiecinski, C. J. (1993). Regional distribution and expression modulation of cytochrome P-450 and epoxide hydrolase mRNAs in the rat brain. Mol. Pharmacol.\n44:990\u2013996.","journal-title":"Mol. Pharmacol."},{"key":"220440_CR129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004714-198808001-00002","volume":"8","author":"P. Seeman","year":"1988","unstructured":"Seeman, P. (1988). Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J. Clin. Psychopharmacol.\n8 (Suppl.):3\u20139.","journal-title":"J. Clin. Psychopharmacol."},{"key":"220440_CR130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2190\/29NP-2XPN-X0ME-MQWU","volume":"25","author":"W. W. Shen","year":"1995","unstructured":"Shen, W. W. (1995). Cytochrome P450 monooxygenases and interactions of psychotropic drugs: A five-year update. Int. J. Psychiatry Medi.\n25:277\u2013290.","journal-title":"Int. J. Psychiatry Medi."},{"key":"220440_CR131","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0006-3223(96)00180-1","volume":"41","author":"W. W. Shen","year":"1997","unstructured":"Shen, W. W. (1997). The metabolism of psychoactive drugs: A review of enzymatic biotransformation and inhibition. Biol Psychiatry\n41:814\u2013826.","journal-title":"Biol Psychiatry"},{"key":"220440_CR132","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0014-2999(67)90065-9","volume":"1","author":"W. Soudijn","year":"1967","unstructured":"Soudijn, W., Van Wijngaarden, I., and Allewijn, F. (1967). Distribution, excretion and metabolism of neuroleptics of the butyrophenone type: part I. Excretion and metabolism of haloperidol and nine related butyrophenone-derivatives in the Wistar rat. Eur. J. Pharmacol.\n1:47\u201357.","journal-title":"Eur. J. Pharmacol."},{"key":"220440_CR133","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/clpt.1984.239","volume":"36","author":"E. Spina","year":"1984","unstructured":"Spina, E., Birgersson, C., von Bahr, C., Ericsson, O., Mellstrom, B., Steiner, E., and Sjoqvist, F. (1984). Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin. Pharmacol. Ther.\n36:677\u2013682.","journal-title":"Clin. Pharmacol. Ther."},{"key":"220440_CR134","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/BF00626371","volume":"41","author":"E. Spina","year":"1991","unstructured":"Spina, E., Martines, C., Caputi, A. P., Cobaleda, J., Pinas, B., Carrillo, J. A., and Benitez, J. (1991). Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur. J. Clin. Pharmacol.\n41:467\u2013470.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"220440_CR135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF00266363","volume":"42","author":"E. Spina","year":"1992","unstructured":"Spina, E., Ancione, M., Di Rosa, A. E., Meduri, M., and Caputi, A. P. (1992a). Polymorphic debrisoquine oxidation and acute neuroleptic induced adverse effects. Eur. J. Clin. Pharmacol.\n42:347\u2013348.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"220440_CR136","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1600-0447.1992.tb03281.x","volume":"86","author":"E. Spina","year":"1992","unstructured":"Spina, E., Sturiale, V., Valvo, S., Ancione, M., Di Rose, A. E., Meduri, M., and Caputi, A. P. (1992b). Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions. Acta Psychiatr. Scand.\n86:364\u2013366.","journal-title":"Acta Psychiatr. Scand."},{"key":"220440_CR137","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1043-6618(05)80063-5","volume":"25","author":"E. Spina","year":"1992","unstructured":"Spina, E., Campo, G. M., Calandra, S., Caputi, A. P., Carrillo, J. A., and Benitez, J. (1992c). Debrisoquine oxidation in an Italian population: A study in healthy subjects and in schizophrenic patients. Pharmacol. Res.\n25:43\u201350.","journal-title":"Pharmacol. Res."},{"key":"220440_CR138","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2165\/00003088-199733060-00004","volume":"33","author":"B. A. Sproule","year":"1997","unstructured":"Sproule, B. A., Naranjo, C. A., Bremner, K. E., and Hassan, P. C. (1997). Selective serotonin reuptake inhibitors and CNS drug interactions: A critical review of the evidence. Clin. Pharmacokinet.\n33:454\u2013471.","journal-title":"Clin. Pharmacokinet."},{"key":"220440_CR139","first-page":"420","volume":"44","author":"G. L. Stimmel","year":"1983","unstructured":"Stimmel, G. L., and Falloon, I. R. (1983). Chlorpromazine plasma levels, adverse effects, and tobacco smoking: Case report. J. Clin. Psychiatry\n44:420\u2013422","journal-title":"J. Clin. Psychiatry"},{"key":"220440_CR140","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0006-291X(90)91936-M","volume":"166","author":"B. Subramanyam","year":"1990","unstructured":"Subramanyam, B., Rollema, H., Woolf, T., and Castagnoli, N., Jr. (1990). Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem. Biophys. Res. Commun.\n166:238\u2013244.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"220440_CR141","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/archpsyc.1974.01760140063010","volume":"31","author":"C. Swett Jr.","year":"1974","unstructured":"Swett, C. Jr., (1974). Drowsiness due to chlorpromazine in relation to cigarette smoking. Arch. Gen. Psychiatry\n31:211\u2013214.","journal-title":"Arch. Gen. Psychiatry"},{"key":"220440_CR142","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archpsyc.1977.01770180047003","volume":"34","author":"C. Swett Jr.","year":"1977","unstructured":"Swett, C. Jr., Cole, J. O., Hartz, S. C., Shapiro, S., and Slone, D. (1977). Hypotension due to chlorpromazine. Relation to cigarette smoking, blood pressure, and dosage. Arch. Gen. Psychiatry\n34:661\u2013663.","journal-title":"Arch. Gen. Psychiatry"},{"key":"220440_CR143","first-page":"89","volume":"22","author":"E. K. G. Syv\u00e4lahti","year":"1986","unstructured":"Syv\u00e4lahti, E. K. G., Lindberg, R., Kallio, J., and de Vocht, M. (1986). Inhibitiory effecs of neuroleptics on debrisoquine oxidation in man. Br. J. Clin. Pharmacol.\n22:89\u201392.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"220440_CR144","first-page":"399","volume":"146","author":"J. L. Tate","year":"1989","unstructured":"Tate, J. L. (1989). Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am. J. Psychiatry\n146:399\u2013400.","journal-title":"Am. J. Psychiatry"},{"key":"220440_CR145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0009-2797(99)00006-X","volume":"118","author":"M. Tugnait","year":"1999","unstructured":"Tugnait, M., Hawes, E. M., McKay, G., Eichelbaum, M., and Midha, K. K. (1999). Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem. Biol. Interact.\n118:171\u2013189.","journal-title":"Chem. Biol. Interact."},{"key":"220440_CR146","first-page":"524","volume":"25","author":"M. Tugnait","year":"1997","unstructured":"Tugnait, M., Hawes, E. M., McKay, G., Rettie, A. E., Haining, R. L., and Midha, K. K. (1997). N-oxidation of clozapine by flavin-containing monooxygenase. Drug Metab. Dispos.\n25:524\u2013527.","journal-title":"Drug Metab. Dispos."},{"key":"220440_CR147","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0021-9673(00)85556-9","volume":"75","author":"P. Turano","year":"1973","unstructured":"Turano, P., Turner, W. J., and Manian, A. A. (1973). Thin-layer chromatography of chlorpromazine metabolites. J. Chromatogr.\n75:277\u2013293.","journal-title":"J. Chromatogr."},{"key":"220440_CR148","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0026-895X(25)12855-1","volume":"40","author":"R. F. Tyndale","year":"1991","unstructured":"Tyndale, R. F., Sunahara, R., Inaba, T., Kalow, W., Gonzalez, F. J., and Niznik, H. B. (1991). Neuronal cytochrome debrisoquine\/sparteine-type oxidation: Potent inhibition of activity by (\u2212)-cocaine and sequence identity to hepatic cytochrome P450 CYP2D6. Mol. Pharmacol.\n40:63\u201368.","journal-title":"Mol. Pharmacol."},{"key":"220440_CR149","first-page":"1401","volume":"152","author":"S. C. Tyson","year":"1995","unstructured":"Tyson, S. C., Devane, C. L., and Risch, S. C. (1995). Pharmacokinetic interaction between risperidone and clozapine. Am. J. Psychiatry\n152:1401\u20131402.","journal-title":"Am. J. Psychiatry"},{"key":"220440_CR150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02245444","volume":"114","author":"L. E. Van Beijsterveldt","year":"1994","unstructured":"Van Beijsterveldt, L. E., Geerts, R. J., Leysen, J. E., Megens, A. A., Van den Eynde, H. M., Meuldermans, W. E., and Heykants, J. J. (1994). Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology\n114:53\u201362.","journal-title":"Psychopharmacology"},{"key":"220440_CR151","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00562905","volume":"11","author":"F. A. J. Vanderheeren","year":"1977","unstructured":"Vanderheeren, F. A. J., and Muusze, R. G. (1977). Plasma levels and half lives of thioridazine and some of its metabolites. Eur. J. Clin. Pharmacol.\n11:135\u2013140.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"220440_CR152","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/tx00039a002","volume":"7","author":"C. J. Van der Schyf","year":"1994","unstructured":"Van der Schyf, C. J., Castagnoli, K., Usuki, E., Fouda, H. G., Rimoldi, J. M., and Castagnoli, N., Jr. (1994). Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL\/6 mice. Chem. Res. Tox.\n7:281\u2013285.","journal-title":"Chem. Res. Tox."},{"key":"220440_CR153","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0304-3940(88)90411-9","volume":"84","author":"B. Volk","year":"1988","unstructured":"Volk, B., Hettmannsperger, U., Papp, Th., Amellizad, Z., Oesch, F., and Knoth, R. (1988). First evidence of cytochrome P-450 induction in the mouse brain by phenytoin. Neurosci. Lett.\n84:219\u2013224.","journal-title":"Neurosci. Lett."},{"key":"220440_CR154","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0306-4522(91)90160-P","volume":"42","author":"B. Volk","year":"1991","unstructured":"Volk, B., Hettmannsperger, U., Papp, Th., Amelizad, Z., Oesch, F., and Knoth, R. (1991). Mapping of phenytoin-inducible cytochrome P450 immunoreactivity in the mouse central nervous system. Neuroscience\n42:215\u2013235.","journal-title":"Neuroscience"},{"key":"220440_CR155","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/clinchem\/39.8.1656","volume":"39","author":"S. A. Volpicelli","year":"1993","unstructured":"Volpicelli, S. A., Centorrino, F., Puopolo, P. R., Kando, J., Frankenburg, F. R., Baldessarini, R. J., and Flood, J. G. (1993). Determination of clozapine, norclozapine, and clozapine-N-oxide in serum by liquid chromatography. Clin. Chem.\n39:1656\u20131659.","journal-title":"Clin. Chem."},{"key":"220440_CR156","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.1991.22","volume":"49","author":"C. von Bahr","year":"1991","unstructured":"von Bahr, C., Movin, G., Nordin, C., Lid\u00e9n, A., Hammarlund-Udenaes, M., Hedberg, A., Ring, H., and Sj\u00f6qvist, F. (1991). Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin. Pharmacol. Ther.\n49:234\u2013240.","journal-title":"Clin. Pharmacol. Ther."},{"key":"220440_CR157","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/0006-2952(85)90533-7","volume":"34","author":"C. von Bahr","year":"1985","unstructured":"von Bahr, C., Spina, E., Birgersson, C., Ericsson, \u00d6., Goransson, M., Henthorn, T., and Sj\u00f6qvist, F. (1985). Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem. Pharmacol.\n34:2501\u20132505.","journal-title":"Biochem. Pharmacol."},{"key":"220440_CR158","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1073\/pnas.91.3.1019","volume":"91","author":"M. Warner","year":"1994","unstructured":"Warner, M., and Gustafssen, J. A. (1994). Effect of ethanol on cytochrome P450 in the rat brain. Proc. Natl. Acad. Sci. USA\n91:1019\u20131023.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"220440_CR159","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1471-4159.1988.tb10573.x","volume":"50","author":"M. Warner","year":"1988","unstructured":"Warner, M., K\u00f6hler, C., Hansson, T., and Gustafsson, J. A. (1988). Regional distribution of cytochrome P-450 in the rat brain: Spectral quantitation and contribution of P-450b, e and P-450c, d. J. Neurochem.\n50:1057\u20131065.","journal-title":"J. Neurochem."},{"key":"220440_CR160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00004714-199802000-00002","volume":"18","author":"H. Wetzel","year":"1998","unstructured":"Wetzel, H., Anghelescu, I., Szegedi, A., Wiesner, J., Weigmann, H., Hartter, S., and Hiemke, C. (1998). Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study. J. Clin. Psychopharmacol.\n18:2\u20139.","journal-title":"J. Clin. Psychopharmacol."},{"key":"220440_CR161","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF00315539","volume":"44","author":"D. Young","year":"1993","unstructured":"Young, D., Midha, K. K., Fossler, M. J., Hawes, E. M., Hubbard, J. W., McKay, G., and Korchinski, E. D. (1993). Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: Implications for the involvement of cytochrome P450IID6. Eur. J. Clin. Pharmacol.\n44:433\u2013438.","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Cellular and Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006938908284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1006938908284\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/A:1006938908284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006938908284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T17:15:50Z","timestamp":1751822150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1006938908284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,8]]},"references-count":161,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["220440"],"URL":"https:\/\/doi.org\/10.1023\/a:1006938908284","relation":{},"ISSN":["0272-4340","1573-6830"],"issn-type":[{"value":"0272-4340","type":"print"},{"value":"1573-6830","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,8]]}}}